secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001804220-24-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD
-------------------------------------------------------------------------------

- Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).
- Dupixent global net sales up 27% to $3.56B; EU approved for COPD; FDA decision expected Sept 27, 2024.
- EYLEA HD/EYLEA U.S. sales $1.53B (+2%), including $304M from EYLEA HD.
- Libtayo global net sales up 42% to $297M; pipeline progress in obesity, gene therapy, oncology.
- New $3B share repurchase authorization; $601M repurchased in Q2; 2024 guidance updated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000026/0001804220-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422024000026/regn-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001804220-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer